An interventional study of Forced-air warming and Intravenous fluid warming in Hypothermia Following Anesthesia, Intraoperative Complications and Body Temperature Changes, sponsored by The Leningrad Regional Clinical Hospital. Recruiting at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by The Leningrad Regional Clinical Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
During long operations on the abdomen, patients often get cold. Doctors call this perioperative hypothermia. Even a small drop in body temperature can cause problems, such as more bleeding, wound infection, and a longer stay in hospital.
To keep patients warm during surgery, doctors usually blow warm air over the body through a special blanket. However, the fluids that patients receive through a vein during surgery are normally at room temperature. These cool fluids may lower the body temperature from the inside.
This study compares two ways of keeping patients warm during operations on the abdomen that last three hours or longer.
Everyone taking part receives warm air blown over the body. In addition, one group receives fluids into a vein at room temperature, about 23 °C, which is the usual practice. The other group receives the same fluids warmed to 39 °C by a special device just before the fluid enters the vein.
Participants are placed into one of the two groups by chance, like flipping a coin. Because of the nature of the treatment, the doctors caring for the patient know which group the patient is in.
The researchers measure body temperature before, during, and at the end of surgery. They also record blood pressure, the medicines used to support blood pressure, the amount of fluid given, the amount of urine produced, and blood tests taken on the day after surgery.
This is a pilot study. Its main purpose is to find out whether a larger study would be possible. The researchers want to learn how many patients can be enrolled, whether the treatment can be given exactly as planned, and how complete the collected information is. The results will be used to plan a larger study.
Design and setting.
Single-centre, randomised, parallel-group, open-label pilot trial conducted at a regional clinical hospital in Saint Petersburg, Russian Federation. Participants are allocated in a 1:1 ratio to a control group or a study group.
Anaesthesia and warming protocol.
All participants receive general anaesthesia according to a standardised institutional protocol, and ambient operating room temperature is kept constant. In both groups, forced-air warming is applied through an upper body blanket at an airflow temperature of 37 °C from induction of anaesthesia until the end of surgery. In the control group, balanced crystalloid solutions are stored at 23 °C and infused without additional warming. In the study group, the same solutions are actively warmed to a target temperature of 39 °C using a medical fluid warmer positioned as close as possible to the venous access site.
Measurements.
Axillary and oesophageal temperature are recorded before induction of anaesthesia, hourly during surgery, and at transfer to the intensive care unit. Haemodynamic variables, the use and infusion rate of norepinephrine, intraoperative crystalloid volume and urine output are recorded throughout surgery. Stroke volume, cardiac output and extracellular fluid volume are assessed by tetrapolar impedance rheography. Base excess, plasma lactate, C-reactive protein and the SOFA score are recorded on the first postoperative day.
Randomisation and allocation concealment.
The allocation sequence is generated using random number tables. Allocation is concealed by sequentially numbered, sealed, opaque envelopes, opened after eligibility is confirmed and written informed consent is obtained. Blinding of the anaesthesia team is not feasible because of the nature of the intervention.
Withdrawal criteria.
Participants are withdrawn from analysis in case of withdrawal of informed consent, errors in data recording, or intraoperative change in the extent of the planned surgical procedure.
Feasibility assessment.
In addition to the clinical outcome measures, the following feasibility parameters are recorded: the proportion of screened patients who are eligible and randomised, the proportion of eligible patients who consent, adherence to the allocated intervention, the proportion of randomised participants with analysable data, and completeness of data for the primary outcome measure. These parameters will be used to determine whether a definitive multicentre trial is feasible and to inform its sample size.
92 studies on the registry are indexed under Intraoperative Complications; 19 are open to participants now.
This study's planned enrollment of 61 is close to the median of 67 across 48 interventional studies indexed under Intraoperative Complications.
Browse Intraoperative Complications studies →The Leningrad Regional Clinical Hospital is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Forced-air warming applied through an upper body blanket at an airflow temperature of 37 °C from induction of anaesthesia until the end of surgery, combined with intravenous infusion of balanced crystalloid solutions stored at 23 °C and administered without additional warming.
Device: Forced-air warming · Other: Unwarmed intravenous fluids
Forced-air warming applied through an upper body blanket at an airflow temperature of 37 °C from induction of anaesthesia until the end of surgery, combined with intravenous infusion of the same balanced crystalloid solutions actively warmed to a target temperature of 39 °C by a medical fluid warmer positioned as close as possible to the venous access site.
Device: Forced-air warming · Device: Intravenous fluid warming
Forced-air warming system with an upper body blanket; airflow temperature set at 37 °C; applied identically in both groups from induction of anaesthesia until the end of surgery.
Also known as: WarmTouch WT-5900
Balanced crystalloid solutions actively warmed to a target temperature of 39 °C using a medical fluid warmer; the infusion line is placed inside the heating element as close as possible to the venous access site.
Also known as: IRIS medical fluid warmer
Balanced crystalloid solutions stored at an ambient temperature of 23 °C and administered intravenously without additional warming.
Core body temperature at admission to the intensive care unit
Oesophageal temperature measured at the time of transfer of the participant from the operating room to the intensive care unit, in degrees Celsius.
Time frame: At transfer to the intensive care unit, up to 12 hours after skin incision
Perioperative axillary temperature
Axillary temperature measured with a contact thermometer. Measured in degrees Celsius.
Time frame: Before induction of anaesthesia, hourly during surgery, and at admission to the intensive care unit, up to 12 hours
Perioperative oesophageal temperature
Core temperature measured with an oesophageal probe. Measured in degrees Celsius.
Time frame: Hourly from 1 hour after start of surgery until admission to the intensive care unit, up to 12 hours
Proportion of participants requiring norepinephrine infusion
Number of participants who received an intraoperative norepinephrine infusion, divided by the number of participants analysed in the group, expressed as a percentage.
Time frame: Intraoperative period, up to 12 hours
Time from skin incision to initiation of norepinephrine infusion
Interval between skin incision and the start of norepinephrine infusion, assessed only in participants who received norepinephrine. Measured in minutes.
Time frame: Intraoperative period, up to 12 hours
Norepinephrine infusion rate
Rate of intraoperative norepinephrine infusion, assessed only in participants who received norepinephrine. Measured in micrograms per kilogram per minute.
Time frame: Intraoperative period, up to 12 hours
Volume of intraoperative crystalloid infusion
Total volume of balanced crystalloid solutions administered intravenously during surgery. Measured in millilitres.
Time frame: From skin incision to end of surgery, up to 12 hours
Intraoperative urine output
Total volume of urine collected during surgery. Measured in millilitres.
Time frame: From skin incision to end of surgery, up to 12 hours
Stroke volume measured by tetrapolar impedance rheography
Stroke volume assessed non-invasively by tetrapolar impedance rheography. Measured in millilitres.
Time frame: From before induction of anaesthesia, hourly during surgery, up to 12 hours
Cardiac output measured by tetrapolar impedance rheography
Cardiac output assessed non-invasively by tetrapolar impedance rheography. Measured in litres per minute.
Time frame: From before induction of anaesthesia, hourly during surgery, up to 12 hours
Change in extracellular fluid volume measured by tetrapolar impedance rheography
Relative change in extracellular fluid volume assessed by tetrapolar impedance rheography. Expressed as a percentage.
Time frame: From start of surgery to end of surgery, up to 12 hours
Base excess in venous blood
Base excess determined by venous blood gas analysis. Measured in millimoles per litre.
Time frame: Postoperative day 1
Plasma lactate concentration
Lactate concentration determined in venous blood. Measured in millimoles per litre.
Time frame: Postoperative day 1
Serum C-reactive protein concentration
C-reactive protein concentration determined in venous blood. Measured in milligrams per litre.
Time frame: Postoperative day 1
Total SOFA score
Sequential Organ Failure Assessment score, calculated as the sum of six organ system subscores. Total score ranges from 0 to 24, with higher scores indicating greater organ dysfunction.
Time frame: Postoperative day 1
Proportion of screened participants who were randomised
Feasibility outcome. Number of randomised participants divided by the number of patients screened for eligibility, expressed as a percentage.
Time frame: From start of enrolment through study completion, up to 32 months
Proportion of eligible participants who provided informed consent
Feasibility outcome. Number of participants who provided written informed consent divided by the number of patients who met the eligibility criteria, expressed as a percentage.
Time frame: From start of enrolment through study completion, up to 32 months
Recruitment rate
Feasibility outcome. Number of randomised participants per month of enrolment.
Time frame: From start of enrolment through study completion, up to 32 months
Adherence to the allocated intervention
Feasibility outcome. Number of randomised participants who received the allocated intervention in full, divided by the number of randomised participants, expressed as a percentage.
Time frame: From start of enrolment through study completion, up to 32 months
Proportion of randomised participants with analysable data
Feasibility outcome. Number of randomised participants whose data were available for analysis of the clinical outcome measures, divided by the number of randomised participants, expressed as a percentage.
Time frame: From start of enrolment through study completion, up to 32 months
Completeness of data for the primary outcome measure
Feasibility outcome. Number of analysed participants with a recorded value of the primary outcome measure, divided by the number of analysed participants, expressed as a percentage.
Time frame: From start of enrolment through study completion, up to 32 months
Plan to share: Yes — De-identified individual participant data underlying the published results will be made available to qualified researchers upon reasonable request to the corresponding author, following approval of a methodologically sound proposal.
Time frame: Beginning 6 months after publication of the main results and ending 3 years thereafter.
Access criteria: Requests should be directed to the corresponding author and will be evaluated on the basis of scientific merit. Data will be shared after approval of a proposal and completion of a data access agreement.
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Apr 2027, 29 months after the start.
Of 27 interventional studies with no phase under Intraoperative Complications, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 53. This study's planned 29 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intraoperative Complications →
The Leningrad Regional Clinical Hospital